Abstract Number: 577 • 2018 ACR/ARHP Annual Meeting
Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis
Background/Purpose: Although biologics represent a major advance in rheumatoid arthritis (RA), many patients fail to achieve adequate responses to these agents. As previous studies have…Abstract Number: 1655 • 2018 ACR/ARHP Annual Meeting
Achieving Remission in Psoriatic Arthritis By Early Initiation of TNF Inhibition: A Double-Blind, Randomized, Placebo-Controlled Trial of Golimumab + Methotrexate Versus Placebo + Methotrexate
Background/Purpose: In inflammatory arthritis such as RA, early initiation of highly effective targeted treatments is a successful strategy to aim for sustained remission.1 Here we…Abstract Number: 2676 • 2018 ACR/ARHP Annual Meeting
SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment
Background/Purpose: In systemic lupus erythematosus (SLE), organ damage is associated with unfavourable disease courses and premature mortality. We aimed at investigating the impact of organ…Abstract Number: 590 • 2018 ACR/ARHP Annual Meeting
Advances in Therapeutic Management with First Biological Therapy in Rheumatoid Arthritis throughout 15 Years
Background/Purpose: In the last two decades the treatment in patients with rheumatoid arthritis (RA) has undergone major advances, especially due to the appearance of new…Abstract Number: 1704 • 2018 ACR/ARHP Annual Meeting
Clinical SLE Disease Activity Index Score of Zero May be a More Pragmatic Outcome Measure in SLE Studies
Background/Purpose: Drug development in systemic lupus erythematosus (SLE) has been challenging. One of the reasons can be traced in the choice of outcome measures. In…Abstract Number: 2823 • 2018 ACR/ARHP Annual Meeting
Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are highly effective treatments for active Rheumatoid Arthritis (RA). However, up to 40% of patients either fail to respond…Abstract Number: 598 • 2018 ACR/ARHP Annual Meeting
Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study
Background/Purpose: Certolizumab-pegol (CZP) is a sixth antitumor necrosis factor inhibitor for rheumatoid arthritis (RA) in Japan. Several clinical trials were conducted to evaluate the efficacy…Abstract Number: 1887 • 2018 ACR/ARHP Annual Meeting
Practice Variation in Prescriptions of Non-TNFi Biologics and Tofacitinib: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Background/Purpose: Biologic DMARDs and tofacitinib account for a large proportion of drug spending in the U.S. Although TNFi drugs have dominated sales, use of…Abstract Number: 2855 • 2018 ACR/ARHP Annual Meeting
Expanding the Phenotype: New Variant in the IL1RN-Gene Associated with Late Onset and Atypical Presentation of Dira
Background/Purpose: Deficiency of the Interleukin-1 receptor antagonist (DIRA) is an autoinflammatory disease of infancy characterized by severe systemic inflammation with bone and skin involvement. This…Abstract Number: 611 • 2018 ACR/ARHP Annual Meeting
Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort
Background/Purpose: After the introduction of Biological Disease-Modifying Anti-Rheumatic-Drugs (bDMARDs) for the treatment of patients with active rheumatoid arthritis (RA), clinical remission has become an achievable…Abstract Number: 2311 • 2018 ACR/ARHP Annual Meeting
Effect of TNF Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate
Background/Purpose: . This study aimed to investigate whether tumor necrosis factor inhibitors (TNFi) have beneficial effects on bone mineral density (BMD) in rheumatoid arthritis (RA)…Abstract Number: 2876 • 2018 ACR/ARHP Annual Meeting
Torque Teno Virus Quantification for Functional Monitoring of Immunomodulation with Biological Compounds in the Treatment of Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) patients who fail to respond to methotrexate (MTX) can be subjected to an addition of biologic disease-modifying antirheumatic drug (bDMARD). Currently…Abstract Number: 619 • 2018 ACR/ARHP Annual Meeting
Patterns of Change of a Second Biological Dmard in a Cohort of Patients with Rheumatoid Arthritis
Background/Purpose: Evaluate the survival of the 2nd biological disease modifying drug (bDMARD)and to determine the causes of suspension of the 2nd bDMARD. Methods: Patients ≥…Abstract Number: 2394 • 2018 ACR/ARHP Annual Meeting
Anti-Adalimumab Antibodies Kinetics: An Early Guide for Juvenile Idiopathic Arthritis (JIA) Switching
Background/Purpose: Anti-adalimumab antibody (AAA) production may lead to reduced adalimumab (ADA) serum levels and therapy failure. There are, however, scarce and conflicting data regarding ADA…Abstract Number: 2907 • 2018 ACR/ARHP Annual Meeting
Comparison of the Joints Ultrasonography in the Patients with Rheumatoid Arthritis Treated By Biological Agents and the Corresponding Synovial Histological Findings
Comparison of the joints ultrasonography in the patients with rheumatoid arthritis treated by biological agents and the corresponding synovial histological findings Background/Purpose: In the treatment…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 26
- Next Page »